肝素对自发性颅内脑出血患者静脉血栓栓塞症的预防效果:一项荟萃分析。

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Therapeutic Advances in Drug Safety Pub Date : 2024-05-22 eCollection Date: 2024-01-01 DOI:10.1177/20420986241253469
Yifu Zhou, Gang Wang, Chunxiao Xue, Guojun He, Yan Zhang, Feilong He, Chenjun He, Xiaosong Liang
{"title":"肝素对自发性颅内脑出血患者静脉血栓栓塞症的预防效果:一项荟萃分析。","authors":"Yifu Zhou, Gang Wang, Chunxiao Xue, Guojun He, Yan Zhang, Feilong He, Chenjun He, Xiaosong Liang","doi":"10.1177/20420986241253469","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) has a serious impact on the prognosis of patients with spontaneous intracranial hemorrhage (sICH). However, the use of prophylactic heparin remains controversial.</p><p><strong>Objectives: </strong>This study investigated the safety and timing of prophylactic heparin for VTE in patients with sICH.</p><p><strong>Design: </strong>This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines.</p><p><strong>Methods: </strong>Two authors systematically searched Web of Science, Cochrane Library, Embase, and PubMed to find all published research before June 2023. The incidence of deep venous thrombosis (DVT) and mortality were set as primary endpoints.</p><p><strong>Results: </strong>This meta-analysis included seven randomized controlled trials (RCTs) and five observational studies involving a total of 4419 sICH patients in the heparin (<i>n</i> = 2808) and control (<i>n</i> = 1183) groups. Among these patients, 205 received early heparin administration, while 223 received late heparin administration. The results suggested that, compared to the control group, patients in the heparin group had a lower incidence of VTE [odds ratio (OR), 0.47; 95% CI, 0.31-0.71; <i>p</i> < 0.001], DVT (OR, 0.53; 95% CI, 0.33-0.85; <i>p</i> = 0.009), pulmonary embolism (OR, 0.31 95% CI, 0.15-0.65; <i>p</i> = 0.002), and mortality (OR, 0.70; 95% CI, 0.54-0.90; <i>p</i> = 0.006), but there were no statistical differences in hematoma enlargement, extracranial hematoma, and major disability (<i>p</i> > 0.05). There was no statistically significant difference in DVT, mortality, hematoma enlargement, and extracranial hemorrhage between the early heparin group (<24-48 h) and the late heparin group (<i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>In patients with sICH, prophylactic use of heparin may be beneficial because it reduces the incidence of VTE and mortality without increasing the risk of additional bleeding. In addition, early prophylactic use of heparin appears to be safe. However, large-scale RCTs are lacking to support this evidence.</p>","PeriodicalId":23012,"journal":{"name":"Therapeutic Advances in Drug Safety","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11113067/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effect of heparin for the prevention of venous thromboembolism in patients with spontaneous intracranial cerebral hemorrhage: a meta-analysis.\",\"authors\":\"Yifu Zhou, Gang Wang, Chunxiao Xue, Guojun He, Yan Zhang, Feilong He, Chenjun He, Xiaosong Liang\",\"doi\":\"10.1177/20420986241253469\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Venous thromboembolism (VTE) has a serious impact on the prognosis of patients with spontaneous intracranial hemorrhage (sICH). However, the use of prophylactic heparin remains controversial.</p><p><strong>Objectives: </strong>This study investigated the safety and timing of prophylactic heparin for VTE in patients with sICH.</p><p><strong>Design: </strong>This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines.</p><p><strong>Methods: </strong>Two authors systematically searched Web of Science, Cochrane Library, Embase, and PubMed to find all published research before June 2023. The incidence of deep venous thrombosis (DVT) and mortality were set as primary endpoints.</p><p><strong>Results: </strong>This meta-analysis included seven randomized controlled trials (RCTs) and five observational studies involving a total of 4419 sICH patients in the heparin (<i>n</i> = 2808) and control (<i>n</i> = 1183) groups. Among these patients, 205 received early heparin administration, while 223 received late heparin administration. The results suggested that, compared to the control group, patients in the heparin group had a lower incidence of VTE [odds ratio (OR), 0.47; 95% CI, 0.31-0.71; <i>p</i> < 0.001], DVT (OR, 0.53; 95% CI, 0.33-0.85; <i>p</i> = 0.009), pulmonary embolism (OR, 0.31 95% CI, 0.15-0.65; <i>p</i> = 0.002), and mortality (OR, 0.70; 95% CI, 0.54-0.90; <i>p</i> = 0.006), but there were no statistical differences in hematoma enlargement, extracranial hematoma, and major disability (<i>p</i> > 0.05). There was no statistically significant difference in DVT, mortality, hematoma enlargement, and extracranial hemorrhage between the early heparin group (<24-48 h) and the late heparin group (<i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>In patients with sICH, prophylactic use of heparin may be beneficial because it reduces the incidence of VTE and mortality without increasing the risk of additional bleeding. In addition, early prophylactic use of heparin appears to be safe. However, large-scale RCTs are lacking to support this evidence.</p>\",\"PeriodicalId\":23012,\"journal\":{\"name\":\"Therapeutic Advances in Drug Safety\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11113067/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20420986241253469\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420986241253469","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:静脉血栓栓塞症(VTE静脉血栓栓塞症(VTE)严重影响自发性颅内出血(sICH)患者的预后。然而,预防性肝素的使用仍存在争议:本研究探讨了自发性颅内出血(sICH)患者预防性使用肝素治疗 VTE 的安全性和时机:本研究遵循系统综述和荟萃分析首选报告项目(PRISMA)报告指南:两位作者系统检索了 Web of Science、Cochrane Library、Embase 和 PubMed,找到了 2023 年 6 月之前发表的所有研究。深静脉血栓(DVT)发生率和死亡率被设定为主要终点:该荟萃分析包括七项随机对照试验(RCT)和五项观察性研究,涉及肝素组(2808 例)和对照组(1183 例)共 4419 例 sICH 患者。在这些患者中,205 人接受了早期肝素治疗,223 人接受了晚期肝素治疗。结果表明,与对照组相比,肝素组患者的 VTE [odds ratio (OR), 0.47; 95% CI, 0.31-0.71; p p = 0.009]、肺栓塞(OR, 0.31 95% CI, 0.15-0.65;P = 0.002)和死亡率(OR,0.70;95% CI,0.54-0.90;P = 0.006),但在血肿扩大、颅外血肿和严重残疾方面没有统计学差异(P > 0.05)。早期肝素组之间在深静脉血栓、死亡率、血肿扩大和颅外出血方面没有统计学差异(P > 0.05):结论:对于 sICH 患者,预防性使用肝素可能是有益的,因为它可以降低 VTE 的发生率和死亡率,同时不会增加额外出血的风险。此外,早期预防性使用肝素似乎是安全的。然而,目前还缺乏大规模的研究性试验来支持这一证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effect of heparin for the prevention of venous thromboembolism in patients with spontaneous intracranial cerebral hemorrhage: a meta-analysis.

Background: Venous thromboembolism (VTE) has a serious impact on the prognosis of patients with spontaneous intracranial hemorrhage (sICH). However, the use of prophylactic heparin remains controversial.

Objectives: This study investigated the safety and timing of prophylactic heparin for VTE in patients with sICH.

Design: This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines.

Methods: Two authors systematically searched Web of Science, Cochrane Library, Embase, and PubMed to find all published research before June 2023. The incidence of deep venous thrombosis (DVT) and mortality were set as primary endpoints.

Results: This meta-analysis included seven randomized controlled trials (RCTs) and five observational studies involving a total of 4419 sICH patients in the heparin (n = 2808) and control (n = 1183) groups. Among these patients, 205 received early heparin administration, while 223 received late heparin administration. The results suggested that, compared to the control group, patients in the heparin group had a lower incidence of VTE [odds ratio (OR), 0.47; 95% CI, 0.31-0.71; p < 0.001], DVT (OR, 0.53; 95% CI, 0.33-0.85; p = 0.009), pulmonary embolism (OR, 0.31 95% CI, 0.15-0.65; p = 0.002), and mortality (OR, 0.70; 95% CI, 0.54-0.90; p = 0.006), but there were no statistical differences in hematoma enlargement, extracranial hematoma, and major disability (p > 0.05). There was no statistically significant difference in DVT, mortality, hematoma enlargement, and extracranial hemorrhage between the early heparin group (<24-48 h) and the late heparin group (p > 0.05).

Conclusion: In patients with sICH, prophylactic use of heparin may be beneficial because it reduces the incidence of VTE and mortality without increasing the risk of additional bleeding. In addition, early prophylactic use of heparin appears to be safe. However, large-scale RCTs are lacking to support this evidence.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety Medicine-Pharmacology (medical)
CiteScore
6.70
自引率
4.50%
发文量
31
审稿时长
9 weeks
期刊介绍: Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信